TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3525270

Group type: EXPERIMENTAL
Intervention: Sucrose meal (50 g) with Acarbose 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sucrose meal (50 g) without Acarbose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sucrose meal (75 g) with Acarbose 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sucrose meal (75 g) without Acarbose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sucrose meal (100 g) with Acarbose 100 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sucrose meal (100 g) without Acarbose
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Acarbose (0 mg, 50 mg, 100 mg, 200 mg) with fixed sucrose load (75 g)
Number of subjects: 9
Study: 31749273

Group type: EXPERIMENTAL
Intervention: Restrictive episiotomy
Number of subjects: 3006

Group type: COMPARATOR
Intervention: Routine episiotomy
Number of subjects: 3006
Study: 29406289

Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy intervention (n = 60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (n = 60)
Number of subjects: 120
Study: 26921093

Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 24613816

Group type: EXPERIMENTAL
Intervention: HFX (hyperfractionation), 81.6 Gy/68 twice‐daily fractions/7 weeks
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: AFX-C (accelerated fractionation continuous), 72 Gy/42 fractions/6 weeks
Number of subjects: 1076

Group type: COMPARATOR
Intervention: SFX (standard fractionation), 70 Gy/35 daily fractions/7 weeks
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: 7-week treatments
Number of subjects: 1076
Study: 24151792

Group type: EXPERIMENTAL
Intervention: Training preschool teachers using a manual covering health education, health promotion, incorporation of oral‐health‐friendly activities into the preschool curriculum, and hands‐on experience of oral examination.
Number of subjects: 72
Study: 21972404

Group type: EXPERIMENTAL
Intervention: CYP2C19 loss-of-function allele carrier
Number of subjects: 371

Group type: COMPARATOR
Intervention: PON1 QQ192
Number of subjects: 371

Group type: COMPARATOR
Intervention: PON1 LL55
Number of subjects: 371
Study: 18435367

Group type: EXPERIMENTAL
Intervention: Finishing with a 30 microm finishing diamond by human operators and mechanical device
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Polishing with Astropol polishing cups by human operators and mechanical device
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Finishing and polishing at baseline and after 48 hours
Number of subjects: 120
Study: 16970691

Group type: EXPERIMENTAL
Intervention: Warm neutral tumescent anesthesia (40 degrees C)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Room-temperature neutral tumescent anesthesia (22 degrees C)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warm nonneutral tumescent anesthesia (pH 4.78)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warm neutral tumescent anesthesia (pH 7.35)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Room-temperature nonneutral tumescent anesthesia
Number of subjects: 36
Study: 14597032

Group type: EXPERIMENTAL
Intervention: IOP lowering by 30%
Number of subjects: 144

Group type: COMPARATOR
Intervention: No IOP-lowering treatment
Number of subjects: 144
Study: 11022197

Group type: EXPERIMENTAL
Intervention: Patients with type 1 diabetes (IDDM)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Reference population
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Male patients with type 1 diabetes (IDDM)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Female patients with type 1 diabetes (IDDM)
Number of subjects: 134
Study: 8810585

Group type: EXPERIMENTAL
Intervention: Do not intervene instructions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Try to stay with the pattern instructions
Number of subjects: 0
Study: 1442914

Group type: EXPERIMENTAL
Intervention: Carbonated lidocaine (10 cm3 of 2%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Deep injection technique with plain lidocaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plain lidocaine (control group from phase 1)
Number of subjects: 100
Study: 3956889

Group type: EXPERIMENTAL
Intervention: Radiotelemetry capsule measurements
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Antisecretory agent
Number of subjects: 4
Study: 30244873

Group type: EXPERIMENTAL
Intervention: Adjuvanted PCV15
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted PCV15
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PCV15 (both formulations)
Number of subjects: 0
Study: 27303064

Group type: EXPERIMENTAL
Intervention: Brain-activating rehabilitation (BAR) conducted for 1 hour, 3 times a week
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 25008086

Group type: EXPERIMENTAL
Intervention: Static magnetic field (SMF) exposure with peak-to-peak magnetic induction of 3 mT and 30 mT m(‐1) gradient for 30 minutes
Number of subjects: 16
Study: 22739624

Group type: EXPERIMENTAL
Intervention: Black soy peptide supplementation (test group, n = 35)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (control group, n = 29)
Number of subjects: 80
Study: 20721420

Group type: EXPERIMENTAL
Intervention: Nursing Consultation Protocol
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 146
Study: 18393051

Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory total score greater than 20
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: One or more prior suicide attempts
Number of subjects: 526
Study: 16542488

Group type: EXPERIMENTAL
Intervention: Exogenous pulmonary surfactant
Number of subjects: 5
Study: 14514406

Group type: EXPERIMENTAL
Intervention: Prophylactic tracheostomy (PT)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Emergent tracheostomy (ET)
Number of subjects: 93
Study: 11071086

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (duration: 72-96 hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Culture positive MEF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Culture negative MEF
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bacteria eradicated
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bacteria persisted
Number of subjects: 20
Study: 8716525

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard positioning
Number of subjects: 50
Study: 1484383

Group type: EXPERIMENTAL
Intervention: Matched strategy (high CCSI score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mismatched strategy (low CCSI score)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choice of strategies
Number of subjects: 0
Study: 3883232

Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31758589

Group type: EXPERIMENTAL
Intervention: Alkali-modified implants
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sandblasted implants
Number of subjects: 14
Study: 30663262

Group type: EXPERIMENTAL
Intervention: WHO International Reference Reagent (89/666)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Whole blood EQA specimen
Number of subjects: 52
Study: 28399035

Group type: EXPERIMENTAL
Intervention: 0.005% tacrolimus eye drops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interferon alpha‐2b (1,000,000 units/cc) eye drops
Number of subjects: 40
Study: 25418873

Group type: EXPERIMENTAL
Intervention: HPV testing in urine
Number of subjects: 216
Study: 23860674

Group type: EXPERIMENTAL
Intervention: 6 weeks above-elbow cast (AEC)
Number of subjects: 47

Group type: COMPARATOR
Intervention: 3 weeks above-elbow cast (AEC) followed by 3 weeks below-elbow cast (BEC)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 6 weeks AEC
Number of subjects: 47

Group type: COMPARATOR
Intervention: 3 weeks AEC followed by 3 weeks BEC
Number of subjects: 47
Study: 21887713

Group type: EXPERIMENTAL
Intervention: Soldier-expressive writing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Soldier-control writing
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Spouse-expressive writing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Spouse-control writing
Number of subjects: 102
Study: 18594971

Group type: EXPERIMENTAL
Intervention: Doxycycline, co-amoxiclav, omeprazole (Group A)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amoxicillin, omeprazole, furazolidone, bismuth (Group B)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Amoxicillin, clarithromycin, omeprazole (Group C)
Number of subjects: 189
Study: 16439432

Group type: EXPERIMENTAL
Intervention: Acetazolamide (4 mg kg(‐1)) + Antioxidants (1 g ascorbic acid i.v. and 200 mg alpha‐tocopherol p.o.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Acetazolamide (4 mg kg(‐1)) + Placebo
Number of subjects: 16
Study: 12890401

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg every 12 hours)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Unfractionated heparin (adjusted doses)
Number of subjects: 50
Study: 11208394

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for 8 weeks, diet restriction, and regular exercise
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks, no behavioral treatment
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cimetidine treatment for 8 weeks followed by 42 months of intervention
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks followed by 42 months of non-intervention
Number of subjects: 55
Study: 9235656

Group type: EXPERIMENTAL
Intervention: Local injections of glucocorticosteroids
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hydrocortisone phonophoresis
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Physiotherapy with sinusoidal modulated currents (SMC)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Laser radiation
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids injections
Number of subjects: 69
Study: 1389662

Group type: EXPERIMENTAL
Intervention: iohexol (intraarterial injection)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ioxaglate (intraarterial injection)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ioxaglate (intravenous injection)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: iohexol (intravenous injection)
Number of subjects: 39
Study: 4048081

Group type: EXPERIMENTAL
Intervention: Self-motivation program with biweekly payroll deductions contingent on meeting self-selected weight-loss goals
Number of subjects: 36

Group type: COMPARATOR
Intervention: Delayed treatment control group
Number of subjects: 36
Study: 30044484

Group type: EXPERIMENTAL
Intervention: Nurse care manager (NCM) strategies during patient interactions
Number of subjects: 41
Study: 28482864

Group type: EXPERIMENTAL
Intervention: Pre- and post-operative physical activity with moderate aerobic activity and inspiratory muscle training (IMT)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Standard care (normal daily exercise routine)
Number of subjects: 640
Study: 26469232

Group type: EXPERIMENTAL
Intervention: Surgical eye (SE)
Number of subjects: 10
Study: 24016496

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1133
Study: 21415660

Group type: EXPERIMENTAL
Intervention: 120 mg etoricoxib (nonsteroidal anti-inflammatory)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4 mg dexamethasone (corticosteroid anti-inflammatory)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (etoricoxib and dexamethasone)
Number of subjects: 50
Study: 18317068

Group type: EXPERIMENTAL
Intervention: Cetuximab 250 mg/m(2) weekly IV and gefitinib 250 mg/d PO
Number of subjects: 13
Study: 16570217

Group type: EXPERIMENTAL
Intervention: Gender-specific HIV prevention intervention (Project FIO)
Number of subjects: 180
Study: 12808176

Group type: EXPERIMENTAL
Intervention: Enoxaparin (mean dose of 0.68 mg/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unfractionated heparin (mean bolus of 42.1 IU/kg and continuous infusion of 57.8 IU/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study: 10475286

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8590960

Group type: EXPERIMENTAL
Intervention: G‐DAMME 250 micrograms IV as a bolus at time 0'
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: hGH 2 IU as an IV bolus at time -180'
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: G‐DAMME preceded by hGH
Number of subjects: 6

Group type: COMPARATOR
Intervention: IV saline
Number of subjects: 6
Study: 1706666

Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 41

Group type: COMPARATOR
Intervention: low-dose epirubicin
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: epirubicin after failure of estramustine phosphate
Number of subjects: 41
Study: 7042201

Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Unable to tolerate antacids
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Medication (antacids or cimetidine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No medications
Number of subjects: 36
Study: 31788783

Group type: EXPERIMENTAL
Intervention: Previous VBAC
Number of subjects: 38686

Group type: EXPERIMENTAL
Intervention: Previous cesarean section for non-cephalic presentation
Number of subjects: 38686

Group type: EXPERIMENTAL
Intervention: Previous cesarean section due to dystocia
Number of subjects: 38686

Group type: EXPERIMENTAL
Intervention: <18 months since last cesarean section
Number of subjects: 38686

Group type: EXPERIMENTAL
Intervention: Model prediction using ROC curve
Number of subjects: 38686
Study: 30834689

Group type: EXPERIMENTAL
Intervention: Topical formulation with di- and tripeptides
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral supplementation based on hydrolyzed collagen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 60
Study: 30059671

Group type: EXPERIMENTAL
Intervention: GS-0976 20 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: GS-0976 5 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: GS-0976
Number of subjects: 126
Study: 26817934

Group type: EXPERIMENTAL
Intervention: Video Interaction Project (VIP)
Number of subjects: 463

Group type: EXPERIMENTAL
Intervention: Building Blocks (BB)
Number of subjects: 463

Group type: COMPARATOR
Intervention: Control
Number of subjects: 463
Study: 25181386

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3307
Study: 21934157

Group type: EXPERIMENTAL
Intervention: Tailored activity pacing instruction
Number of subjects: 32

Group type: COMPARATOR
Intervention: General activity pacing instruction
Number of subjects: 32
Study: 20855168

Group type: EXPERIMENTAL
Intervention: Web-Enhanced Behavioral Self-Management program (WEB-SM)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 118
Study: 17667837

Group type: EXPERIMENTAL
Intervention: Acticoat dressings
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5% sulfamylon-soaked burn wound dressings
Number of subjects: 20
Study: 16135475

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 57
Study: 11981362

Group type: EXPERIMENTAL
Intervention: Once-daily SQV-SGC/RTV (1600/100 mg)
Number of subjects: 69
Study: 10420097

Group type: COMPARATOR
Intervention: Group A (greater MMN amplitudes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B (lower MMN amplitudes)
Number of subjects: 0
Study: 7551972

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 0
Study: 2043500

Group type: EXPERIMENTAL
Intervention: DHAP (dexamethasone/high‐dose cytarabine/cisplatin) for two courses at 3‐ to 4‐week intervals
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ABMT (autologous bone marrow transplantation) following DHAP
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Event-free survival for patients undergoing transplantation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall study group
Number of subjects: 50
Study: 6118769

Group type: EXPERIMENTAL
Intervention: Washing after birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bathing after birth
Number of subjects: 0
Study: 31096925

Group type: COMPARATOR
Intervention: Traditional triage algorithm
Number of subjects: 42542

Group type: COMPARATOR
Intervention: Triage algorithm with clinical assessment and vital signs
Number of subjects: 42542

Group type: COMPARATOR
Intervention: Triage algorithm with routine biomarkers
Number of subjects: 42542

Group type: EXPERIMENTAL
Intervention: suPAR biomarker
Number of subjects: 42542
Study: 28697991

Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg before surgery
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (no carbamazepine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Addicted patients (no treatment)
Number of subjects: 90
Study: 26244705

Group type: EXPERIMENTAL
Intervention: Block randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stratified randomization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Minimization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic hierarchical randomization
Number of subjects: 0
Study: 23586805

Group type: EXPERIMENTAL
Intervention: Low-construal mindset (considering learning from proximity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-construal mindset (considering learning from temporal distance)
Number of subjects: 0
Study: 21592946

Group type: EXPERIMENTAL
Intervention: Active use of stereotypes to make predictions met with reward and punishment
Number of subjects: 320

Group type: COMPARATOR
Intervention: Noise-based accounts
Number of subjects: 320

Group type: COMPARATOR
Intervention: Discrepancy-reducing feedback learning
Number of subjects: 320

Group type: COMPARATOR
Intervention: Simulations
Number of subjects: 320
Study: 19700669

Group type: EXPERIMENTAL
Intervention: Northwestern Anagram Test (NAT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 18193497

Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 115
Study: 12914622

Group type: EXPERIMENTAL
Intervention: Pacing + Shock
Number of subjects: 11

Group type: COMPARATOR
Intervention: Shock Only
Number of subjects: 11
Study: 10950231

Group type: EXPERIMENTAL
Intervention: 2.5 mg oral insulin daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 7.5 mg oral insulin daily
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study: 9210279

Group type: EXPERIMENTAL
Intervention: Feminist-cognitive-behavioral treatment
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Process-psychodynamic treatment
Number of subjects: 218
Study: 1422321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 0.15 mg/day of conjugated estrogens
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 0.30 mg/day of conjugated estrogens
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 0.15 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 0.30 mg/day of conjugated estrogens plus 600 mg/day of ipriflavone
Number of subjects: 133
Study: 4045362

Group type: EXPERIMENTAL
Intervention: Automatic sphygmomanometer
Number of subjects: 14

Group type: COMPARATOR
Intervention: Hawksley random zero instrument
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cuff position for the automatic instrument
Number of subjects: 14
Study: 3435694

Group type: EXPERIMENTAL
Intervention: Sustained release verapamil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional formulation of verapamil
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 10
Study: 31613320

Group type: EXPERIMENTAL
Intervention: Higher dose (HD) group took 4 mg 17ß‐estradiol/d orally.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lower dose (LD) group took 2 mg 17ß‐estradiol/d orally and placebo.
Number of subjects: 20
Study: 29675680

Group type: EXPERIMENTAL
Intervention: Ruxolitinib plus capecitabine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo plus capecitabine
Number of subjects: 149
Study: 29200984

Group type: EXPERIMENTAL
Intervention: Carbohydrate solution (CHO)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (CON)
Number of subjects: 8
Study: 26034927

Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid (ALA) 600 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 24103510

Group type: EXPERIMENTAL
Intervention: Iron and copper syrup with zinc (10 mg of iron, 0.5 mg of copper, and 10 mg of zinc)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Iron and copper syrup without zinc (10 mg of iron and 0.5 mg of copper)
Number of subjects: 251
Study: 20947155

Group type: EXPERIMENTAL
Intervention: C‐SE etch
Number of subjects: 29

Group type: COMPARATOR
Intervention: C‐SE non‐etch
Number of subjects: 29
Study: 18230263

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (Control Group)
Number of subjects: 90
Study: 16340688

Group type: EXPERIMENTAL
Intervention: NIDCAP model of care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional care
Number of subjects: 0
Study: 14566254

Group type: EXPERIMENTAL
Intervention: Uncoated oxygenator (UnModified Surface)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Oxygenator coated with BioPassive Surface
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Oxygenator coated with BioActive Surface
Number of subjects: 71

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 71